Hold on to Piramal Health: Seshadri Bharathan

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd.

What would you do with Piramal Health at 493?

Seshadri Bharathan: I sense this is hold but depends on the clarity on the dividend amount and the usage of funds. We remain confident about the CRAMs and in business of the company and the stock currently trades around 15 times their FY12 earnings and 19 times their FY11 earnings, so my sense is that being one of the leading companies in pharmaceutical space, investors should stay invested in this stock.